ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2021 Atypical Hemolytic Uremic Syndrome Epidemiology Forecast to 2030 - ResearchAndMarkets.com

November 8, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Nov 8, 2021--

The “Atypical Hemolytic Uremic Syndrome(aHUS) - Epidemiology Forecast to 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the disease, historical and forecasted Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Key Findings

In the year 2020, the total prevalent cases of Atypical Hemolytic Uremic Syndrome was 7.0 thousand cases in the 7MM which are expected to grow during the study period, i.e., 2018-2030.

ADVERTISEMENT

The disease epidemiology covered in the report provides historical as well as forecasted Atypical Hemolytic Uremic Syndrome epidemiology [segmented as Total Prevalent Cases of Atypical hemolytic uremic syndrome, Total Diagnosed Cases of Atypical hemolytic uremic syndrome, Total Age group-specific Cases of Atypical hemolytic uremic syndrome, and Total Treated Cases of Atypical hemolytic uremic syndrome] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Atypical Hemolytic Uremic Syndrome (aHUS) Epidemiology

Estimates show that the highest cases of Atypical Hemolytic Uremic Syndrome in the 7MM were in the United States, followed by Germany, France, Italy, Spain, the United Kingdom, and Japan in 2020.

  • In the United States, the total number of prevalent cases of Atypical Hemolytic Uremic Syndrome was 3.5 thousand cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
  • In the year 2020, the total prevalent cases of Atypical Hemolytic Uremic Syndrome were 3.1 thousand cases in EU-5 which are expected to grow during the study period, i.e., 2018-2030.
  • In Japan, the total number of prevalent cases of Atypical Hemolytic Uremic Syndrome was 452 cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.

Scope of the Report

ADVERTISEMENT

  • The Atypical Hemolytic Uremic Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The Atypical Hemolytic Uremic Syndrome Report and Model provide an overview of the risk factors and global trends of Atypical Hemolytic Uremic Syndrome in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Atypical Hemolytic Uremic Syndrome in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Atypical Hemolytic Uremic Syndrome.
  • The report provides the segmentation of the Atypical Hemolytic Uremic Syndrome epidemiology by total prevalent cases in the 7MM.
  • The report provides the segmentation of the Atypical Hemolytic Uremic Syndrome epidemiology by total diagnosed cases in the 7MM.
  • The report provides the segmentation of the Atypical Hemolytic Uremic Syndrome epidemiology by total age group-specific cases in the 7MM.
  • The report provides the segmentation of the Atypical Hemolytic Uremic Syndrome epidemiology by total treated cases in the 7MM.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population of Atypical Hemolytic Uremic Syndrome?
  • What are the key findings of the Atypical Hemolytic Uremic Syndrome epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018-2030)?
  • What would be the total number of patients of Atypical Hemolytic Uremic Syndrome across the 7MM during the study period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2018-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Atypical Hemolytic Uremic Syndrome?

Reasons to Buy

The Atypical Hemolytic Uremic Syndrome Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Atypical Hemolytic Uremic Syndrome market
  • Quantify patient populations in the global Atypical Hemolytic Uremic Syndrome market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Atypical Hemolytic Uremic Syndrome therapeutics in each of the markets covered
  • Understand the magnitude of Atypical Hemolytic Uremic Syndrome population by its age group-specificity
  • The Atypical Hemolytic Uremic Syndrome epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Atypical Hemolytic Uremic Syndrome Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hmqkh2

View source version on businesswire.com:https://www.businesswire.com/news/home/20211108005852/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 11/08/2021 12:13 PM/DISC: 11/08/2021 12:13 PM

http://www.businesswire.com/news/home/20211108005852/en